Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies

A class of Alzheimer's disease drugs currently studied in clinical trials appears to reduce damage caused by traumatic brain injury in animals, researchers at Georgetown University Medical Center report in an upcoming advance online publication of Nature Medicine.

15 Mar 2009

Phylonix granted broad U.S. patent for assessing cardiac functions in Zebrafish

Phylonix Pharmaceuticals announced, at the Society of Toxicology Annual Meeting in Baltimore, that the U.S. Patent and Trademark Office has issued the company a broad patent for assessing the toxicity of pharmaceutical test agents on cardiovascular functions in zebrafish.

15 Mar 2009

Small molecules block cancer gene

Finding molecules that block the activity of the oncogene Stat 3 (signal transducer and activator of transcription) required screening literally millions of compounds, using computers that compared the structure of the cancer-causing gene to those of the small molecules, said a Baylor College of Medicine researcher in a report that appears in the current online issue of the journal PLoS One (Public Library of Science ONE).

11 Mar 2009

Scientists discover key molecules that inhibit viral production

The research, led by Professor Donny Strosberg of Scripps Florida, was published on March 4, 2009, in the Journal of General Virology's advance, online edition, Papers in Press.

11 Mar 2009

Eating lots of vegetables reduces risk of prostate cancer

In the online edition of Molecular Nutrition and Food Research, Ruth Chan and collaborators provided a review on prostate cancer (CaP) and vegetable consumption.

8 Mar 2009

FDA accepts IND application for Tigris Pharmaceutical's GGTI-2418

Tigris Pharmaceuticals, Inc., has announced that its Investigational New Drug (IND) application for the Company's geranylgeranyltransferase inhibitor (GGTI-2418) has been accepted by the U.S. Food and Drug Administration.

4 Mar 2009

New clues about mitochondrial 'growth spurts'

Mitochondria are restless, continually merging and splitting. But contrary to conventional wisdom, the size of these organelles depends on more than fusion and fission, as Berman et al. show. Mitochondrial growth and degradation are also part of the equation.

2 Mar 2009

Nanoparticles detect dying cancer cells

Two years ago, researchers at the University of South Australia discovered a new molecular marker specific for chemotherapy-induced cancer cell death. Now, those same investigators have used this marker to develop an imaging agent that can pinpoint tumor cell death using magnetic resonance imaging.

23 Feb 2009

An adjuvant chemotherapeutic agent in gastric cancer therapy

Peritoneal carcinomatosis can be thought of as a series of events that together form a peritoneal metastatic cascade.

18 Feb 2009

Scientists discover missing link in the way cells protect themselves against cancer

Cancer Research UK scientists have discovered a missing link in the way cells protect themselves against cancer, according to research published in Genes & Development.

5 Feb 2009

Disruption of circadian clock can suppress cancer growth

Researchers at the University of North Carolina at Chapel Hill have shown that disruption of the circadian clock - the internal time-keeping mechanism that keeps the body running on a 24-hour cycle - can slow the progression of cancer.

3 Feb 2009

New technology rapidly detects tumor response to chemotherapy

New technology developed by Duke University bioengineers can help clinicians more precisely detect whether specific cancer drugs are working, and should give basic researchers a powerful new tool to better understand the underlying mechanisms of cancer development.

2 Feb 2009

New potential targets for colitis-associated cancer

Recent research from the laboratory of Michael Karin, PhD, at the University of California, San Diego School of Medicine - the first researcher to demonstrate a molecular link between inflammation and cancer - has identified two potential targets for the prevention and treatment of colitis-associated cancer (CAC), the most serious complication of inflammatory bowel disease.

2 Feb 2009

Inflammation in colon may get doused before fueling cancer development

A tiny molecule found in most plant-based foods douses the flames before damaging lesions can form in the colon, according to a study by Texas AgriLife Research scientist Dr. Nancy Turner.

2 Feb 2009

Study shows how defective DNA repair triggers 2 neurological diseases

Scientists at St. Jude Children's Research Hospital have teased apart the biological details distinguishing two related neurological diseases-ataxia telangiectasia-like disease (ATLD) and Nijmegen breakage syndrome (NBS).

15 Jan 2009

Discovery of protein that amplifies cell death

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified a small intracellular protein that helps cells commit suicide.

15 Jan 2009

Discovery of protein that amplifies cell death

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified a small intracellular protein that helps cells commit suicide.

15 Jan 2009

Theraputic target for prostate cancer

The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.

14 Jan 2009

Variations in mismatch repair genes predict prognosis in pancreatic cancer

Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from The University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

13 Jan 2009

Maslinic acid from olive-skin pomace protects against colon cancer

Researchers from the University of Granada and the University of Barcelona have shown that treatment with maslinic acid, a triterpenoid compound isolated from olive-skin pomace, results in a significant inhibition of cell proliferation and causes apoptotic death in colon-cancer cells.

8 Jan 2009